Literature DB >> 19353699

The importance of gamma-glutamyltransferase activity in patients with coronary artery disease.

Sabri Demircan1, Mustafa Yazici, Kenan Durna, Fethi Kilicaslan, Serdar Demir, Mesut Pinar, Okan Gulel.   

Abstract

BACKGROUND: In this study, we sought to investigate the relation of gamma-glutamyltransferase (GGT) levels with the significance of coronary artery disease (CAD), clinical presentation, left ventricular (LV) function, and inflammatory activity.
METHODS: A total of 235 patients (mean age: 60.1 +/- 10.5 years, 166 [70%] males) who had coronary angiography were included in the study. Patients who had CAD constituted the study group (Group 1, n=189) and patients who had insignificant coronary disease or normal coronary activity constituted the control group (Group 2, n=46).
RESULTS: GGT levels were higher in Group 1 than Group 2 (38.7 +/- 30.9 U/L versus 27.5 +/- 17.5 U/L, p =0.025). Left ventricular ejection fraction (LVEF) was lower in Group 1 than Group 2 (52.6% +/- 11.7% versus 58.8% +/- 11.3%, p < 0.002). GGT activity (40.2 +/- 32.5 U/L versus 29.1 +/- 18.3 U/L, p < 0.002) and c-reactive protein (CRP) levels (33.9 +/- 43.6 mg/dl versus 17.8 +/- 29.8 mg/dl, p < 0.002) were higher, LVEF (52.6% +/- 12.1% versus 56.5% +/- 11.0%, p =0.021) was lower in patients with acute coronary syndrome compared with stable CAD group. In regression analysis, CRP levels (p < 0.0001, odds ratio [OR]=3.77, 95% confidence interval [CI] 0.10 < OR < 0.32), LVEF (p =0.016, OR=- 2.44, 95% CI - 0.95 < OR < - 0.10) and LV end-diastolic pressure (p =0.015, OR=4.31, 95% CI - 1.19 < OR < - 0.13) were independent predictors of GGT activity.
CONCLUSIONS: The increased GGT activity is related to LV function, clinical stability, and inflammatory activity rather than the severity of CAD. Measurement of GGT activity may be useful in predicting cardiovascular risk.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19353699      PMCID: PMC6652977          DOI: 10.1002/clc.20345

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  6 in total

1.  The prognostic role of gamma-glutamyltransferase activity in non-diabetic ST-elevation myocardial infarction.

Authors:  Chiara Lazzeri; Serafina Valente; Roberto Tarquini; Marco Chiostri; Claudio Picariello; Gian Franco Gensini
Journal:  Intern Emerg Med       Date:  2010-09-29       Impact factor: 3.397

2.  Gamma glutamyl transferase activity: relationship with thoracic aortic intima media thickness and inflammation.

Authors:  M Caylı; M Gür; G Y Kalkan; Z Elbasan; D Y Sahin; N Y Koyunsever; C Türkoğlu; T Seker; O Kaypaklı; H Harbalıoğlu; H Uçar
Journal:  Herz       Date:  2013-08-11       Impact factor: 1.443

3.  Effect of atorvastatin on the expression of gamma-glutamyl transferase in aortic atherosclerotic plaques of apolipoprotein E-knockout mice.

Authors:  Gang Li; Xiao-wei Wu; Wei-hua Lu; Rong Ai; Fang Chen; Zhong-zhi Tang
Journal:  BMC Cardiovasc Disord       Date:  2014-10-18       Impact factor: 2.298

4.  Evaluation of gamma glutamyl transferase as a marker of cardiovascular risk, in 200 angiographically proven coronary artery disease patients.

Authors:  Vani Bharani; V Ramesh; Ram Nawal Rao; Satyendra Tewari
Journal:  Indian Heart J       Date:  2017-03-25

5.  Comparison of the effects of metoprolol or carvedilol on serum gamma-glutamyltransferase and uric acid levels among patients with acute coronary syndrome without ST segment elevation.

Authors:  Lütfü Aşkın; Şule Karakelleoğlu; Hüsnü Değirmenci; Selami Demirelli; Ziya Şimşek; Muhammed Hakan Taş; Selim Topçu; Zakir Lazoğlu
Journal:  Anatol J Cardiol       Date:  2016-01       Impact factor: 1.596

6.  Serum Gamma Glutamyltransferase Is Associated with 25-Hydroxyvitamin D Status in Elderly Patients with Stable Coronary Artery Disease.

Authors:  Aleksander Danikiewicz; Bartosz Hudzik; Justyna Nowak; Joanna Kowalska; Iwona Zieleń-Zynek; Janusz Szkodzinski; Han Naung Tun; Barbara Zubelewicz-Szkodzinska
Journal:  Int J Environ Res Public Health       Date:  2020-12-02       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.